All In Biotech

Drug Trial Radar · NCT02625389

A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

132

Actual

Start

Nov 29, 2017

Primary completion

May 12, 2021

Study completion May 12, 2021

Sponsor

Lead sponsor
GuerbetIndustry
Sponsor type
Industry
First posted
Dec 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter phase IV Post-Marketing Study. The study is designed to investigate the safety of Lipiodol® Ultra Fluid in association with surgical glues used according to each site medical practice of vascular embolization. Subjects will be enrolled with the main condition that a procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues is part of their therapeutic/palliative strategy for their disease. The vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue will be administered as study procedure. According to the patient need and health status a second vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue may be considered by the investigator within the next 30 days after the first one. In this case, this procedure will be considered as a second study procedure. The per-procedure safety evaluation will be enabled by appropriate records of safety events during the time frame of the procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues. Safety evaluation will be completed with safety records within 30 +/-3 days after the embolization procedure. Efficacy evaluation will rely on the level of lesion(s) obliteration after embolization compared to the pre-procedural target level of obliteration. Exploratory descriptive statistical methods will be used to evaluate safety and efficacy, using both the total population and subsets of subjects with similar clinical conditions.

Conditions

  • Congenital Hemangioma
  • Hemangioendothelioma
  • Angiosarcoma
  • Arteriovenous Malformations

Interventions

  • Lipiodol Ultra Fluid with surgical gluesDrug

    Lipiodol Ultra Fluid and surgical glue mixture administered via selective arterial catheterization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Drug Reactions During the Embolization ProcedureTime frame: Collected between administration of the mixture and catheterization laboratory discharge (up to 1 day)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • KLES Dr. Prabhakar Kore Hospital

    Belagavi, India

  • Victoria Hospital

    Bengaluru, India

  • Mazumdar Shaw medical Centre

    Bengaluru, India

  • Mahatma Gandhi Missions Medical college and Hospital

    Chhatrapati Sambhajinagar, India

  • Apollo Hospital

    Hyderabad, India

  • AIIMS

    Jodhpur, India

  • Sanjay Gandhi Post Graduate Institute of Meducal Sciences (SGPGI)

    Lucknow, India

  • Government Medical College

    Nagpur, India

  • BLK Super Speciality Hospital

    New Delhi, India

  • AIIMS

    New Delhi, India

  • B.J Govt College & Sassoon Hospitals

    Pune, India

  • KEM Hospital

    Pune, India

  • 7 Orange Hospitals

    Pune, India

  • Geetanjali Medical College and Hospital

    Udaipur, India

  • Acharya Vinobha Bhave Hospital

    Wardha, India

  • Division of Peripheral Vascular & Endovascular sciences, Medanta-The Medicity Hospital

    Gurgaon, Haryana, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.